End-to-End Preclinical and Translational CNS Imaging

Perceptive Discovery delivers integrated CNS imaging and biomarker capabilities that bridge preclinical research with early clinical translation. Our teams combine advanced in vivo imaging with radiochemistry and target-validation assays to generate high-quality data that supports confident decision-making.

From biodistribution, occupancy, and pharmacodynamic studies to volumetric imaging and radioligand binding, we provide end-to-end support that accelerates neuroscience programs toward IND readiness.

We work across a broad range of CNS indications, including Alzheimer’s disease, Parkinson’s disease, depression, and neuroinflammation, enabling smarter discovery and translation for small molecules, biologics, and gene or RNA therapies.

Comprehensive In Vivo CNS Imaging Expertise

• 11,000+ studies completed, including neurology and neurodegeneration models
• Full suite of in vivo CNS imaging modalities: PET, SPECT, MRI, CT, BLI, FMRI, cryofluorescence tomography (CFT)
• Quantitative biomarker imaging for target engagement, neurotransmitter release, and volumetric brain analysis
• Experience with small molecules, ASOs, siRNA, antibodies, and viral vectors (e.g., AAVs)
• Multi-species expertise: rodents, non-human primates, and transgenic models